YD Bio Ltd
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
YD Bio Ltd (YDES) - Total Liabilities
Latest total liabilities as of June 2025: $19.00 Million USD
Based on the latest financial reports, YD Bio Ltd (YDES) has total liabilities worth $19.00 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
YD Bio Ltd - Total Liabilities Trend (2020–2024)
This chart illustrates how YD Bio Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
YD Bio Ltd Competitors by Total Liabilities
The table below lists competitors of YD Bio Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Endurance RP Limited
PINK:RPGLF
|
USA | $4.90 Million |
|
TREDEGAR
BE:T70
|
Germany | €284.09 Million |
|
YOC - Dusseldorf Stock Exchang
DU:YOC
|
Germany | €10.91 Million |
|
Jse Ltd
BE:JF6
|
Germany | €55.40 Billion |
|
MAZDA MOTOR CORP - Dusseldorf Stock Exchang
DU:MZA
|
Germany | €2.03 Trillion |
|
Top Win International Limited Ordinary Shares
NASDAQ:TOPW
|
USA | $5.25 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down YD Bio Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how YD Bio Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for YD Bio Ltd (2020–2024)
The table below shows the annual total liabilities of YD Bio Ltd from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $273.98K | -8.13% |
| 2023-12-31 | $298.22K | -95.57% |
| 2022-12-31 | $6.74 Million | -26.03% |
| 2021-12-31 | $9.11 Million | -48.88% |
| 2020-12-31 | $17.81 Million | -- |